News | August 19, 2008

Philips Leads euHeart Project for Personalized Diagnosis, Treatment of Cardiovascular Disease

August 20, 2008 - Royal Philips Electronics said today it will lead a new European Union-funded research project called “euHeart”, which is aimed at improving the diagnosis, therapy planning and treatment of cardiovascular disease - one of the biggest causes of mortality in the western world.

By targeting the diagnosis and treatment phases of the care cycles for heart conditions such as heart failure, coronary artery disease, heart rhythm disorders, and congenital heart defects, the euHeart project complements the recently announced HeartCycle project, also led by Philips, which focuses on the long term management of chronic heart disease patients.

The euHeart consortium aims to develop advanced computer models of the human heart that can be personalized to patient-specific conditions using clinical data from various sources, such as CT and MRI scans, measurements of blood flow and blood pressure in the coronary arteries, and ECGs. These computer models will integrate the behavior of the heart and the aorta at molecular, cellular, tissue and organ-level. They will also incorporate clinical knowledge about how cardiovascular disease disturbs the correct functioning of the heart at these levels. As a result, it may be possible to develop simulation tools that doctors can use to predict the outcome of different types of therapy, and because the models will be personalized to individual patients, the therapy could be equally personalized.

“euHeart is a very exciting project that will bring together the latest advances in modeling and computing to improve the care of patients with heart disease,” says Professor Reza Razavi, the project’s clinical coordinator who is also professor of paediatric cardiovascular science and head of the division of imaging sciences at King’s College London. “It may ultimately allow us to select and optimize the best treatment for individual patients.”

As an example, one way of treating heart rhythm disorders is a minimally invasive procedure known as radio-frequency ablation. During this procedure, a catheter is inserted into the patient’s heart and the tissue responsible for propagating abnormal electrical signals through the heart muscle is destroyed using heat from a radio-frequency field generated at the tip of the catheter. At the moment, doctors have to rely on their experience to decide which areas of tissue to destroy – a task that is complicated by the fact that the electrical activity in every patient’s heart is subtly different. With the aid of a computerized model that reflects the patient’s unique heart structure and function, doctors may be able to test the results of destroying different areas of tissue before they have to operate on the patient.

The euHeart consortium comprises public and private partners from 16 research, academic, industrial and medical organizations from six different European countries. It will run for four years and has a budget of about 19 million euros, of which approximately 14 million will be provided by the EU as part of the EU Seventh Framework Program. The project forms part of the Virtual Physiological Human (VPH) initiative - a collaborative effort that aims to produce a computer model of the entire human body so that it can be investigated as a single complex system.

Within the multidisciplinary euHeart consortium, the University of Oxford is the scientific coordinator of the project, while King's College London leads the clinical program.

For more information: www.research.philips.com/newscenter/backgrounders/080820-euheart.html,

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init